AbbVie Inc. vs United Airlines Holdings, Inc.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and United Airlines Holdings, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating United Airlines Holdings, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and United Airlines Holdings, Inc. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $59.1B for United Airlines Holdings, Inc., while their respective market capitalizations stand at $451.5B and $38.2B. AbbVie Inc. is headquartered in United States and United Airlines Holdings, Inc. operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

United Airlines Holdings, Inc.: A network airline is a coordination machine. United's value comes from putting the right aircraft, crew, schedules, airport slots, loyalty incentives, and corporate contracts together so thousands of connecting markets become sellable every day.

AbbVie Inc. and United Airlines Holdings, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and United Airlines Holdings, Inc..

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

United Airlines Holdings, Inc. business model: United makes money from passenger tickets, premium cabins, basic economy, cargo, MileagePlus loyalty economics, co-branded credit card revenue, baggage and seat fees, United Club memberships, and partner revenue. Hubs create network density that lets the airline fill aircraft and price global itineraries.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of United Airlines Holdings, Inc..

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

United Airlines Holdings, Inc. competitive advantage: United's advantage is its hub network, international route breadth, Star Alliance connectivity, premium-cabin expansion, MileagePlus loyalty base, corporate account strength, and major positions at airports such as Chicago O'Hare, Newark, Denver, Houston, San Francisco, Washington Dulles, and Los Angeles.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and United Airlines Holdings, Inc. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

United Airlines Holdings, Inc. growth strategy: United is investing in premium seating, larger aircraft, international routes, operational reliability, MileagePlus, airport clubs, digital service, Starlink connectivity, and network depth at core hubs.

A closer look at the financial trajectory of AbbVie Inc. and United Airlines Holdings, Inc. rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

United Airlines Holdings, Inc.: United's 2025 total operating revenue was USD 59.1 billion, up 3.5%. Operating income was USD 4.7 billion. Passenger revenue rose 3.1% as passengers increased 4.3% and capacity increased 6.1%, while other operating revenue grew 10.4% helped by loyalty and club revenue.